The guidelines are divided in two parts: PART I covers cutaneous T-cell lymphoma, chronic graft-versus-host disease and acute graft-versus-host disease while PART II will cover scleroderma, solid organ transplantation, Crohn's disease, use of ECP in paediatrics practice, atopic dermatitis, type 1 diabetes, pemphigus, epidermolysis bullosa acquisita and erosive oral lichen planus.Įxtracorporeal photopheresis (ECP, also known as extracorporeal photochemotherapy, extracorporeal photoimmunotherapy or just photopheresis) is a leukapheresis-based therapy that is available at more than 200 centres worldwide. These updated 2020 guidelines provide at present the most comprehensive available expert recommendations for the use of extracorporeal photopheresis based on the available published literature and expert consensus opinion.

All authors had the opportunity to review each contribution as it was added.

This was done using the recognized and approved guidelines of EDF for this task. In order to further provide recognized expert practical guidelines for the use of this technology for all indications, the European Dermatology Forum (EDF) again proceeded to address these questions in the hands of the recognized experts within and outside the field of dermatology. It has confirmed recognition in well-known documented conditions such as graft-versus-host disease after allogeneic bone marrow transplantation, systemic sclerosis, solid organ transplant rejection including lung, heart and liver and to a lesser extent inflammatory bowel disease. After the publication of the first guidelines for this technology in the JEADV in 2014, this technology has maintained additional promise in the treatment of other severe and refractory conditions in a multi-disciplinary setting. Zic have nothing to disclose.įollowing the first investigational study on the use of extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma published in 1983, this technology has received continued use and further recognition for additional earlier as well as refractory forms. Zuckermann reports personal fees from Therakos-Mallinckrodt, outside the submitted work. Zouboulis reports personal fees from AccureAcne, Allergan, Almirall, Bayer Healthcare, General Topics, GSK/Stiefel, Idorsia, Incyte, Jafra Cosmetics, Janssen, Jenapharm, L'OREAL, Regeneron, and Sobi personal fees and honoraria to his employer for his participation to clinical studies from AbbVie, Galderma, Novartis, InflaRx, NAOS-BIODERMA, Pierre Fabre, PPM and UCB and honoraria to his employer for his participation to clinical studies from AOTI and AstraZeneca. Wolf reports grants and other from AbbVie, other from Almirall, other from Amgen, other from Celgene, other from Eli Lilly, other from Janssen-Cilag, other from Kwizda, other from Leo Pharma, other from Merck Sharp & Dohme, other from Novartis, other from Sanofi-Aventis, grants and other from Pfizer, and personal fees from Therakos, during the conduct of the study. Knobler reports Speaker fees from Mallinckrodt-Therakos. Guenova reports personal fees from Mallinckrodt, outside the submitted work. Greinix reports personal fees from Mallinckrodt, Novartis, Roche, Amgen and Celgene, during the conduct of the study. Gniadecki reports personal fees from Mallinckrodt, during the conduct of the study personal fees from Lilly personal fees and other from AbbVie grants and personal fees from Sanofi personal fees from Sun Pharma and personal fees from Janssen, outside the submitted work. Gennery reports grants from Mallinkrodt, during the conduct of the study. Bohbot reports other from Therakos during the conduct of the study. BAGOT has a patent Anti-KIR3DL2 antibody licensed. BAGOT reports personal fees from Kyowa Kirin, Takeda, Helsinn and Innate Pharma, outside the submitted work. Arun reports research from Mallinckrodt Ltd and personal fees from Mallinckrodt Ltd, outside the submitted work.Dr.

Jafra skin programmer manual